Targeting apoptosis as an approach for gastrointestinal cancer therapy

Drug Resistance Updates

Volumn 12, Issue 3, 2009, Pages 55-64

  Qiao, Liang ^a   Wong, Benjamin C Y ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Apoptosis; Colon cancer; Gastric cancer; Therapy

Indexed keywords

AMG 655; ANTINEOPLASTIC AGENT; APO 010; APOMAB; BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FAS ANTIGEN; FAS LIGAND; FASARET; FLUOROURACIL; FOLINIC ACID; GEFITINIB; INHIBITOR OF APOPTOSIS PROTEIN 2; IRINOTECAN; LEXATUMUMAB; MAPATUMUMAB; MATUZUMAB; MITOGEN ACTIVATED PROTEIN KINASE; OBLIMERSEN; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; SURVIVIN; TNFERADE; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; CACHEXIA; CANCER CHEMOTHERAPY; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DOWN REGULATION; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG POTENTIATION; HUMAN; HYPOTENSION; LOW DRUG DOSE; METASTASIS; MULTIPLE ORGAN FAILURE; PANCREAS CANCER; PRIORITY JOURNAL; RECTUM CANCER; STOMACH CANCER;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL SURVIVAL; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; GASTROINTESTINAL NEOPLASMS; HUMANS; MODELS, BIOLOGICAL; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION;

EID: 67349150698     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drup.2009.02.002     Document Type: Article

References (181)

1. Aljada A., O'Connor L., Fu Y.Y., and Mousa S.A. PPARgamma ligands, rosiglitazone and pioglitazone inhibit bFGF- and VEGF-mediated angiogenesis. Angiogenesis 11 (2008) 361-367
2. Anand P., Sundaram C., Jhurani S., Kunnumakkara A.B., and Aggarwal B.B. Curcumin and cancer: an "old-age" disease with an "age-old" solution. Cancer Lett. 267 (2008) 133-164
3. Antonsson B., and Martinou J.C. The Bcl-2 protein family. Exp. Cell Res. 256 (2000) 50-57
4. Arkenau H.T., Brunetto A.T., Barriuso J., Olmos D., Eaton D., de Bono J., Judson I., et al. Clinical benefit of new targeted agents in Phase I trials in patients with advanced colorectal cancer. Oncology 76 (2009) 151-156
5. Ashkenazi A. Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev. 19 (2008) 325-331
6. Bachleitner-Hofmann T., Sun M.Y., Chen C.T., Tang L., Song L., Zeng Z., et al. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells. Mol. Cancer Ther. 7 (2008) 3499-3508
7. Bae S.H., Ryoo H.M., Kim M.K., Lee K.H., Sin J.I., and Hyun M.S. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapeutic agents in gastric cancer cell lines. Oncol. Rep. 19 (2008) 1027-1032
8. Binion D.G., Otterson M.F., and Rafiee P. Curcumin inhibits VEGF mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibition. Gut 57 (2008) 1509-1517
9. Blanquicett C., Roman J., and Hart C.M. Thiazolidinediones as anti-cancer agents. Cancer Ther. 6 (2008) 25-34
10. Board R.E., Williams V.S., Knight L., Shaw J., Greystoke A., Ranson M., et al. Isolation and extraction of circulating tumor DNA from patients with small cell lung cancer. Ann. N.Y. Acad. Sci. 1137 (2008) 98-107
11. Borralho P.M., Moreira da Silva I.B., Aranha M.M., Albuquerque C., Nobre Leitão C., Steer C.J., et al. Inhibition of Fas expression by RNAi modulates 5-fluorouracil-induced apoptosis in HCT116 cells expressing wild-type p53. Biochim. Biophys. Acta 1772 (2007) 40-47
12. Bowen J.M., Gibson R.J., Keefe D.M., and Cummins A.G. Cytotoxic chemotherapy upregulates pro-apoptotic Bax and Bak in the small intestine of rats and humans. Pathology 37 (2005) 56-62
13. Boyiadzis M., and Foon K.A. Approved monoclonal antibodies for cancer therapy. Expert Opin. Biol. Ther. 8 (2008) 1151-1158
14. Brockman J.A., Gupta R.A., and Dubois R.N. Activation of PPARγ leads to inhibition of anchorage-independent growth of human colorectal cancer cells. Gastroenterology 115 (1998) 1049-1055
15. Bukholm I.K., and Nesland J.M. Protein expression of p53, p21 (WAF1/CIP1), bcl-2, Bax, cyclin D1 and pRb in human colon carcinomas. Virchows Arch. 436 (2000) 224-228
16. Cai Y.C., Jiang Z., Vittimberga F., Xu X., Savas L., and Woda B. Expression of transforming growth factor-alpha and epidermal growth factor receptor in gastrointestinal stromal tumours. Virchows Arch. 435 (1999) 112-115
17. Call J.A., Eckhardt S.G., and Camidge D.R. Targeted manipulation of apoptosis in cancer treatment. Lancet Oncol. 9 (2008) 1002-1011
18. Camidge D.R. Apomab: an agonist monoclonal antibody directed against Death Receptor 5/TRAIL-Receptor 2 for use in the treatment of solid tumors. Expert Opin. Biol. Ther. 8 (2008) 1167-1176
19. Carlo-Stella C., Lavazza C., Locatelli A., Vigano L., Gianni A.M., and Gianni L. Targeting TRAIL agonistic receptors for cancer therapy. Clin. Cancer Res. 13 (2007) 2313-2317
20. Carter B.Z., Gronda M., Wang Z., Welsh K., Pinilla C., and Andreeff M. Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells. Blood 105 (2005) 4043-4050
21. Chen T., and Deng C. Inhibitory effect of siRNA targeting survivin in gastric cancer MGC-803 cells. Int. Immunopharmacol. 8 (2008) 1006-1011
22. Cheng A.L., Hsu C.H., Lin J.K., Hsu M.M., Ho Y.F., Shen T.S., et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 21 (2001) 2895-2900
23. Chiacchiera F., and Simone C. Signal-dependent regulation of gene expression as a target for cancer treatment: inhibiting p38alpha in colorectal tumors. Cancer Lett. 265 (2008) 16-26
24. Cummins J.M., Kohli M., Rago C., Kinzler K.W., Vogelstein B., and Bunz F. X-linked inhibitor of apoptosis protein (XIAP) is a nonredundant modulator of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human cancer cells. Cancer Res. 64 (2004) 3006-3008
25. Cunningham D., Humblet Y., Siena S., Khayat D., Bleiberg H., Santoro A., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351 (2004) 337-345
26. Dai Y., Qiao L., Chan K.W., Zou B., Ma J., Lan H.Y., et al. Loss of XIAP sensitizes Rosiglitazone-induced growth inhibition of colon cancer in vivo. Int. J. Cancer 122 (2008) 2858-2863
27. D'Alessandro A., Pieroni L., Ronci M., D'Aguanno S., Federici G., and Urbani. Proteasome inhibitors therapeutic strategies for cancer. Recent Pat. Anticancer Drug Discov. 4 (2009) 73-82
28. de Bono J.S., and Rowinsky E.K. Therapeutics targeting signal transduction for patients with colorectal carcinoma. Br. Med. Bull. 64 (2002) 227-254
29. de Haas E.C., di Pietro A., Simpson K.L., Meijer C., Suurmeijer A.J., Lancashire L.J., et al. Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer. Neoplasia 10 (2008) 1041-1048
30. Durai R., Yang S.Y., Sales K.M., Seifalian A.M., Goldspink G., and Winslet M.C. Insulin-like growth factor binding protein-4 gene therapy increases apoptosis by altering Bcl-2 and Bax proteins and decreases angiogenesis in colorectal cancer. Int. J. Oncol. 30 (2007) 883-888
31. Dutton A., Young L.S., and Murray P.G. The role of cellular FLICE inhibitory protein (c-FLIP) in the pathogenesis and treatment of cancer. Expert Opin. Ther. Targets 10 (2006) 27-35
32. Eberle J., Kurbanov B.M., Hossini A.M., Trefzer U., and Fecker L.F. Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches. Drug Resist. Updates 10 (2007) 218-234
33. Ebert E.C., and Groh V. Dissection of spontaneous cytotoxicity by human intestinal intraepithelial lymphocytes: MIC on colon cancer triggers NKG2D-mediated lysis through Fas ligand. Immunology 124 (2008) 33-41
34. Ebert M.P., and Röcken C. First steps towards molecular prevention in gastric carcinogenesis. Cancer Biol. Ther. 6 (2007) 276-277
35. Endo K., Kohnoe S., Tsujita E., Watanabe A., Nakashima H., and Baba H. Modulation of anti-apoptosis by endogenous IAP expression in MKN45 human gastric cancer cells. Anticancer Res. 25 (2005) 2713-2717
36. Endo T., Abe S., Seidlar H.B., Nagaoka S., Takemura T., Utsuyama M., et al. Expression of IAP family proteins in colon cancers from patients with different age groups. Cancer Immunol. Immunother. 53 (2004) 770-776
37. Fang J.Y., and Richardson B.C. The MAPK signalling pathways and colorectal cancer. Lancet Oncol. 6 (2005) 322-327
38. Frankel S.R. Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis. Semin. Oncol. 30 (2003) 300-304
39. Fujita T., Doihara H., Washio K., Ino H., Murakami M., Naito M., et al. Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cells. Anticancer Drugs 18 (2007) 677-686
40. Fujiwara Y., Higuchi K., Hamaguchi M., Takashima T., Watanabe T., Tominaga K., et al. Increased expression of transforming growth factor-alpha and epidermal growth factor receptors in rat chronic reflux esophagitis. J. Gastroenterol. Hepatol. 9 (2004) 521-527
41. Garm Spindler K.L., Pallisgaard N., Rasmussen A.A., Lindebjerg J., Andersen R.F., Crüger D., et al. The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer. Ann. Oncol. 29 (2009) (Epub ahead of print)
42. Goel A., Kunnumakkara A.B., and Aggarwal B.B. Curcumin as "Curecumin": from kitchen to clinic. Biochem. Pharmacol. 75 (2008) 787-809
43. Goel S., Mani S., and Perez-Soler R. Tyrosine kinase inhibitors: a clinical perspective. Curr. Oncol. Rep. 4 (2002) 9-19
44. Gonçalves A., Esteyries S., Taylor-Smedra B., Lagarde A., Ayadi M., Monges G., et al. A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment. BMC Cancer 8 (2008) 169
45. Guichard S.M., Hua M.L., Kang P., Macpherson J.S., and Jodrell D.I. Short hairpin RNAs targeting Bcl-xL modulate senescence and apoptosis following SN-38 and irinotecan exposure in a colon cancer model. Cancer Chemother. Pharmacol. 60 (2007) 651-660
46. Guo B., Godzik A., and Reed J.C. Bcl-G, a novel pro-apoptotic member of the Bcl-2 family. J. Biol. Chem. 276 (2001) 2780-2785
47. Hafner C., Reichle A., and Vogt T. New indications for established drugs: combined tumor-stroma-targeted cancer therapy with PPARγ agonists, COX-2 inhibitors, mTOR antagonists and metronomic chemotherapy. Curr. Cancer Drug Targets 5 (2005) 393-419
48. Hague A., Hicks D.J., Hasan F., Smartt H., Cohen G.M., Paraskeva C., et al. Increased sensitivity to TRAIL-induced apoptosis occurs during the adenoma to carcinoma transition of colorectal carcinogenesis. Br. J. Cancer 92 (2005) 736-742
49. Hatcher H., Planalp R., Cho J., Torti F.M., and Torti S.V. Curcum: from ancient medicine to current clinical trials. Cell. Mol. Life Sci. 65 (2008) 1631-1652
50. Hecht J.R. Current and emerging therapies for metastatic colorectal cancer: applying research findings to clinical practice. Am. J. Health Syst. Pharm. 65 (2008) S15-S21
51. Hecht J.R., Patnaik A., Berlin J., Venook A., Malik I., Tchekmedyian S., et al. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer 110 (2007) 980-988
52. Hoshino R., Chatani Y., Yamori T., Tsuruo T., Oka H., Yoshida O., et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 21 (1999) 813-822
53. Huang E.H., and Wicha M.S. Colon cancer stem cells: implications for prevention and therapy. Trends Mol. Med. 14 (2008) 503-509
54. Humphreys R.C. Development and evaluation of cancer therapeutic agents targeting TRAIL receptor 1 and 2. In: LaRochelle W.J., and Shimkets R.A. (Eds). Cancer Drug Discovery and Development: The Oncogenomics Handbook (2005), Humana Press, Totawa 659-676
55. Hunter A.M., LaCasse E.C., and Korneluk R.G. The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 12 (2007) 1543-1668
56. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350 23 (2004) 2335-2342
57. Iannolo G., Conticello C., Memeo L., and De Maria R. Apoptosis in normal and cancer stem cells. Crit. Rev. Oncol. Hematol. 66 (2008) 42-51
58. Ikeguchi M., Liu J., and Kaibara N. Expression of survivin mRNA and protein in gastric cancer cell line (MKN-45) during cisplatin treatment. Apoptosis 7 (2002) 23-29
59. Jean G.W., and Shah S.R. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer. Pharmacotherapy 28 (2008) 742-754
60. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., Feuer E.J., and Thun M.J. Cancer statistics, 2005. CA Cancer J. Clin. 55 (2005) 10-30
61. Jiang X.H., Lam S.K., Lin M.C., Jiang S.H., Kung H.F., Slosberg E.D., et al. Novel target for induction of apoptosis by cyclo-oxygenase-2 inhibitor SC-236 through a protein kinase C-β(1)-dependent pathway. Oncogene 21 (2002) 6113-6122
62. Jimeno A., Messersmith W.A., Hirsch F.R., Franklin W.A., and Eckhardt S.G. KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J. Clin. Oncol. 5 (2009) (Epub ahead of print)
63. Johnson J.J., and Mukhtar H. Curcumin for chemoprevention of colon cancer. Cancer Lett. 255 (2007) 170-181
64. Johnstone R.W., Frew A.J., and Smyth M.J. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat. Rev. Cancer 8 (2008) 782-798
65. Kanzler S., Trarbach T., and Heinemann V. Results of a phase 2 trial of HGS-ETR1 (agonistic human monoclonal antibody to TRAIL receptor 1) in subjects with relapsed or refractory colorectal cancer (CRC). Proceedings of the 13th European Cancer Organisation Conference, October 20-November 3. Paris, France (2005) (Abstract No: 630)
66. Karameris A., Kanavaros P., Aninos D., Gorgoulis V., Mikou G., Rokas T., Niotis M., and Kalogeropoulos N. Expression of epidermal growth factor (EGF) and epidermal growth factor receptor (EGFR) in gastric and colorectal carcinomas. An immunohistological study of 63 cases. Pathol. Res. Pract. 189 (1993) 133-137
67. Karikari C.A., Roy I., Tryggestad E., Feldmann G., Pinilla C., Welsh K., et al. Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein. Mol. Cancer Ther. 6 (2007) 957-966
68. Katoh M., and Katoh M. WNT signaling pathway and stem cell signaling network. Clin. Cancer Res. 13 (2007) 4042-4045
69. Kim R., Emi M., Matsuura K., and Tanabe K. Therapeutic potential of antisense (AS) Bcl-2 as a chemosensitizer for patients with gastric and breast carcinoma. Gan To Kagaku Ryoho 32 (2005) 1540-1545
70. Kim R., Emi M., Tanabe K., and Toge T. Preclinical evaluation of antisense Bcl-2 as a chemosensitizer for patients with gastric carcinoma. Cancer 101 (2004) 2177-2186
71. Kim T. Technology evaluation: Matuzumab, Merck KGaA. Curr. Opin. Mol. Ther. 6 (2004) 96-103
72. Kim J.H., Go H.Y., Jin D.H., Kim H.P., Hong M.H., Chung W.Y., et al. Inhibition of the PI3K-Akt/PKB survival pathway enhanced an ethanol extract of Rhus verniciflua Stokes-induced apoptosis via a mitochondrial pathway in AGS gastric cancer cell lines. Cancer Lett. 265 (2008) 197-205
73. Klasa R.J., Gillum A.M., Klem R.E., and Frankel S.R. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev. 12 (2002) 193-213
74. Kopp R., Rothbauer E., Ruge M., Arnholdt H., Spranger J., Muders M., et al. Clinical implications of the EGF receptor/ligand system for tumor progression and survival in gastrointestinal carcinomas: evidence for new therapeutic options. Recent Results Cancer Res. 162 (2003) 115-132
75. Kopp R., Rothbauer E., Mueller E., Schildberg F.W., Jauch K.W., and Pfeiffer A. Reduced survival of rectal cancer patients with increased tumor epidermal growth factor receptor levels. Dis. Colon Rectum 46 (2003) 1391-1399
76. Korkolopoulou P., Saetta A.A., Levidou G., Gigelou F., Lazaris A., Thymara I., et al. c-FLIP expression in colorectal carcinomas: association with Fas/FasL expression and prognostic implications. Histopathology 51 (2007) 150-156
77. Krajewska M., Moss S.F., Krajewski S., Song K., Holt P.R., and Reed J.C. Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas. Cancer Res. 56 (1996) 2422-2427
78. Kucharczak J., Simmons M.J., Fan Y., and Gelinas C. To be, or not to be: NF-κB is the answer-role of Rel/NF-κB in the regulation of apoptosis. Oncogene 22 (2003) 8961-8982
79. Kuniyasu H., Yoshida K., Sasaki T., Sasahira T., Fujii K., and Ohmori H. Conjugated linoleic acid inhibits peritoneal metastasis in human gastrointestinal cancer cells. Int. J. Cancer 118 (2006) 571-576
80. Kuraoka K., Matsumura S., Sanada Y., Nakachi K., Imai K., Eguchi H., et al. A single nucleotide polymorphism in the extracellular domain of TRAIL receptor DR4 at nucleotide 626 in gastric cancer patients in Japan. Oncol. Rep. 14 (2005) 465-470
81. LaCasse E.C., Mahoney D.J., Cheung H.H., Plenchette S., Baird S., and Korneluk R.G. IAP-targeted therapies for cancer. Oncogene 27 (2008) 6252-6275
82. LaCasse E.C., Cherton-Horvat G.G., Hewitt K.E., Jerome L.J., Morris S.J., Kandimalla E.R., et al. Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis. Clin. Cancer Res. 12 (2006) 5231-5241
83. Lam L.T., Davis R.E., Ngo V.N., et al. Compensatory IKKalpha activation of classical NF-kappaB signaling during IKKbeta inhibition identified by an RNA interference sensitization screen. Proc. Natl. Acad. Sci. U.S.A. 105 (2008) 20798-20803
84. Langemeijer S.M., de Graaf A.O., and Jansen J.H. IAPs as therapeutic targets in haematological malignancies. Expert Opin. Ther. Targets 12 (2008) 981-993
85. Lee D.S., Kang S.B., Baek J.T., Nam S.W., Lee K.M., Ahn B.M., et al. Immunohistochemical expression of bcl-2, bcl-xL, bax, p53 proteins in gastric adenoma and adenocarcinoma. Korean J. Gastroenterol. 45 (2005) 394-400
86. Lejeune F.J., Liénard D., Matter M., and Rüegg C. Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun. 6 (2006) 6
87. Lemoine N.R., and McNeish I.A. Gene transfer: Bax to the future for cancer therapy. Gut 53 (2004) 478-479
88. Lenz H.J. First-line combination treatment of colorectal cancer with hepatic metastases: choosing a targeted agent. Cancer Treat. Rev. 34 (2008) S3-S7
89. Lim S.C. Fas-related apoptosis in gastric adenocarcinoma. Oncol. Rep. 10 (2003) 57-63
90. Lin H.L., Yang M.H., Wu C.W., Chen P.M., Yang Y.P., Chu Y.R., et al. 2-Methoxyestradiol attenuates phosphatidylinositol 3-kinase/Akt pathway-mediated metastasis of gastric cancer. Int. J. Cancer 121 (2007) 2547-2555
91. LoPiccolo J., Blumenthal G.M., Bernstein W.B., and Dennis P.A. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist. Updates 11 (2008) 32-50
92. Lorenzo H.K., and Susin S.A. Therapeutic potential of AIF-mediated caspase-independent programmed cell death. Drug Resist. Updates 10 (2007) 235-255
93. Lu C.D., Altieri D.C., and Tanigawa N. Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res. 58 (1998) 1808-1812
94. Lynch P.M. Chemoprevention with special reference to inherited colorectal cancer. Fam. Cancer 7 (2008) 59-64
95. Macarulla T., Casado E., Ramos F.J., Valverde C., and Tabernero J. Epidermal growth factor receptor (EGFR) inhibitors in gastrointestinal cancer. Onkologie 29 (2006) 99-105
96. Malecka-Panas E., Kordek R., Biernat W., Tureaud J., Liberski P.P., and Majumdar A.P. Differential activation of total and EGF receptor (EGF-R) tyrosine kinase (tyr-k) in the rectal mucosa in patients with adenomatous polyps, ulcerative colitis and colon cancer. Hepatogastroenterology 44 (1997) 435-440
97. Martin J.H., Potthoff A., Ledig S., Cornberg M., Jandl O., Manns M.P., et al. Effect of H. pylori on the expression of TRAIL, FasL and their receptor subtypes in human gastric epithelial cells and their role in apoptosis. Helicobacter 9 (2004) 371-386
98. Matar P., Rojo F., Cassia R., Moreno-Bueno G., Di Cosimo S., and Tabernero J. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin. Cancer Res. 10 (2004) 6487-6501
99. Mayer R. Targeted therapy for advanced colorectal cancer-more is not always better. N. Engl. J. Med. 360 (2009) 623-625
100. McConkey D.J., and Zhu K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist. Updates 11 (2008) 164-179
101. McKenna W.G., Muschel R.J., Gupta A., Hahn S., and Bernhard E.J. Signaling inhibition with radiation in colorectal cancer: clinical trials. Semin. Oncol. 30 (2003) 56-67
102. Mercier I., Vuolo M., Jasmin J.F., Medina C.M., Williams M., and Mariadason J.M. ARC (apoptosis repressor with caspase recruitment domain) is a novel marker of human colon cancer. Cell Cycle 7 (2008) 1640-1647
103. Micha D., Cummings J., Shoemaker A., Elmore S., Foster K., Greaves M., et al. Circulating biomarkers of cell death after treatment with the BH-3 mimetic ABT-737 in a preclinical model of small-cell lung cancer. Clin. Cancer Res. 14 (2008) 7304-7310
104. Michl P., and Downward J. Mechanisms of disease: PI3K/AKT signaling in gastrointestinal cancers. Z. Gastroenterol. 43 (2005) 1133-1139
105. Milano A., Vincenzo R., and Caponigro F. The proteasome: a worthwhile target for the treatment of solid tumors?. Eur. J. Cancer 43 (2007) 1125-1133
106. Mita M.M., Ochoa L., Rowinsky E.K., Kuhn J., Schwartz G., Hammond L.A., et al. A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer. Ann. Oncol. 17 (2006) 313-321
107. Mollinedo F., and Gajate C. Fas/CD95 death receptor and lipid rafts: new targets for apoptosis-directed cancer therapy. Drug Resist. Updates 9 (2006) 51-73
108. Moragoda L., Jaszewski R., and Majumdar A.P. Curcumin induced modulation of cell cycle and apoptosis in gastric and colon cancer cells. Anticancer Res. 21 (2001) 873-878
109. Moreira J.N., Santos A., and Simões S. Bcl-2-targeted antisense therapy (Oblimersen sodium): towards clinical reality. Rev. Recent Clin. Trials 1 (2006) 217-235
110. Mori T., Doi R., Kida A., Nagai K., Kami K., Ito D., et al. Effect of the XIAP inhibitor Embelin on TRAIL-induced apoptosis of pancreatic cancer cells. J. Surg. Res. 142 (2007) 281-286
111. Nachmias B., Ashhab Y., and Ben-Yehuda D. The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer. Semin. Cancer Biol. 14 (2004) 231-243
112. Nagashima H., Mori M., Sadanaga N., Mashino K., Yoshikawa Y., and Sugimachi K. Expression of Fas ligand in gastric carcinoma relates to lymph node metastasis. Int. J. Oncol. 18 (2001) 1157-1162
113. Nikrad M., Johnson T., Puthalalath H., Coultas L., Adams J., and Kraft A.S. The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim. Mol. Cancer Ther. 4 (2005) 443-449
114. Nishigaki H., Wada K., Tatsuguchi A., Sueoka N., Futagami S., Gudis K., et al. ErbB2 without erbB3 expression in metaplastic columnar epithelium of Barrett's esophagus. Digestion 70 (2004) 95-102
115. O'Dwyer P.J., and Benson III A.B. Epidermal growth factor receptor-targeted therapy in colorectal cancer. Semin. Oncol. 29 (2002) 10-17
116. Oliver L., and Vallette F.M. The role of caspases in cell death and differentiation. Drug Resist. Updates 8 (2005) 163-170
117. Osaki M., Kase S., Kodani I., Watanabe M., Adachi H., and Ito H. Expression of Fas and Fas ligand in human gastric adenomas and intestinal-type carcinomas: correlation with proliferation and apoptosis. Gastric Cancer 4 (2001) 198-205
118. Osaki M., Kase S., Adachi K., Takeda A., Hashimoto K., and Ito H. Inhibition of the PI3K-Akt signaling pathway enhances the sensitivity of Fas-mediated apoptosis in human gastric carcinoma cell line, MKN-45. J. Cancer Res. Clin. Oncol. 130 (2004) 8-14
119. Ostrowska H. The ubiquitin-proteasome system: a novel target for anticancer and anti-inflammatory drug research. Cell. Mol. Biol. Lett. 13 (2008) 353-365
120. Papouchado B., Erickson L.A., Rohlinger A.L., Hobday T.J., Erlichman C., Ames M.M., et al. Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas. Mod. Pathol. 18 (2005) 1329-1335
121. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 55 (2005) 74-108
122. Patel D.K. Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer. Pharmacotherapy 28 (2008) 31S-41S
123. Pennati M., Folini M., and Zaffaroni N. Targeting survivin in cancer therapy. Expert Opin. Ther. Targets 12 (2008) 463-476
124. Plummer R., Attard G., Pacey S., Li L., Razak A., Perrett R., et al. Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin. Cancer Res. 13 (2007) 6187-6194
125. Pro B., Leber B., Smith M., Fayad L., Romaguera J., Hagemeister F., et al. Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma. Br. J. Haematol. 143 (2008) 355-360
126. Pukac L., Kanakaraj P., Humphreys R., Alderson R., Bloom M., Sung C., et al. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumor types in vitro and in vivo. Br. J. Cancer 92 (2005) 1430-1441
127. Qiao L., Li G.H., Dai Y., Wang J., Li Z., Zou B., et al. Gene expression profile in colon cancer cells with respect to XIAP expression status. Int. J. Colorectal Dis. 24 (2009) 245-260
128. Qiao L., Dai Y., Chan K.W., Ma J., Lin M.C.M., Lan H.Y., et al. XIAP deficiency sensitizes PPARγ ligand-induced killing of colon cancer cells. Mol. Cancer Ther. 7 (2008) 2203-2211
129. Qiao L., Dai Y., Gu Q., Chan K.W., Ma J., Lan H.Y., et al. Loss of XIAP sensitizes colon cancer cells to PPARγ independent antitumor effects of troglitazone and 15-PGJ2. Cancer Lett. 268 (2008) 260-271
130. Qiao L., Studer E., Leach K., McKinstry R., Gupta S., Decker R., et al. Deoxycholic acid (DCA) causes ligand-independent activation of epidermal growth factor receptor (EGFR) and FAS receptor in primary hepatocytes: inhibition of EGFR/mitogen-activated protein kinase-signaling module enhances DCA-induced apoptosis. Mol. Biol. Cell 12 (2001) 2629-2645
131. Rashmi R., Kumar S., and Karunagaran D. Human colon cancer cells lacking Bax resist curcumin-induced apoptosis and Bax requirement is dispensable with ectopic expression of Smac or downregulation of Bcl-XL. Carcinogenesis 26 (2005) 713-723
132. Reed J.C. Mechanisms of apoptosis avoidance in cancer. Curr. Opin. Oncol. 11 (1999) 68-75
133. Roccaro A.M., Vacca A., and Ribatti D. Bortezomib in the treatment of cancer. Recent Pat. Anticancer Drug Discov. 1 (2006) 397-403
134. Rojo F., Tabernero J., Albanell J., Van Cutsem E., Ohtsu A., Doi T., et al. Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. J. Clin. Oncol. 24 (2006) 4309-4016
135. Rychahou P.G., Murillo C.A., and Evers B.M. Targeted RNA interference of PI3K pathway components sensitizes colon cancer cells to TNF-related apoptosis-inducing ligand (TRAIL). Surgery 138 (2005) 391-397
136. Saif M.W., Elfiky A., and Salem R.R. Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann. Surg. Oncol. 14 (2007) 1860-1869
137. Sasaki T., Fujii K., Yoshida K., Shimura H., Sasahira T., Ohmori H., and Kuniyasu H. Peritoneal metastasis inhibition by linoleic acid with activation of PPARγ in human gastrointestinal cancer cells. Virchows Arch. 16 (2005) 1-6
138. Schimmer A.D., Dalili S., Batey R.A., and Riedl S.J. Targeting XIAP for the treatment of malignancy. Cell Death Differ. 13 (2006) 179-188
139. Schwartsmann G., Di Leone L.P., Dal Pizzol F., and Roesler R. MAPK pathway activation in colorectal cancer: a therapeutic opportunity for GRP receptor antagonists. Lancet Oncol. 6 (2005) 444-445
140. Shirao K., Yoshino T., Boku N., Kato K., Hamaguchi T., Yasui H., et al. A phase I escalating single-dose and weekly fixed-dose study of cetuximab pharmacokinetics in Japanese patients with solid tumors. Cancer Chemother. Pharmacol. 24 (2009) (Epub ahead of print)
141. Singh S., and Khar A. Biological effects of curcumin and its role in cancer chemoprevention and therapy. Anticancer Agents Med. Chem. 6 (2006) 259-370
142. Sinicrope F.A., Penington R.C., and Tang X.M. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis is inhibited by Bcl-2 but restored by the small molecule Bcl-2 inhibitor, HA 14-1, in human colon cancer cells. Clin. Cancer Res. 10 (2004) 8284-8292
143. Sträter J., and Möller P. CD95 (Fas/APO-1)/CD95L in the gastrointestinal tract: fictions and facts. Virchows Arch. 442 (2003) 218-225
144. Tabruyn S.P., and Griffioen A.W. NF-kappa B: a new player in angiostatic therapy. Angiogenesis 11 (2008) 101-106
145. Tedesco K.L., Lockhart A.C., and Berlin J.D. The epidermal growth factor receptor as a target for gastrointestinal cancer therapy. Curr. Treat. Options Oncol. 5 (2004) 393-403
146. Thorburn A., Behbakht K., and Ford H. TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them. Drug Resist. Updates 11 (2008) 17-24
147. Tol J., Koopman M., Cats A., Rodenburg C.J., Creemers G.J.M., Schrama J.G., et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N. Engl. J. Med. 360 (2009) 563-572
148. Tominaga K., Higuchi K., Sasaki E., Suto R., Watanabe T., Fujiwara Y., et al. Correlation of MAP kinases with COX-2 induction differs between MKN45 and HT29 cells. Aliment. Pharmacol. Ther. 20 (2004) 143-150
149. Tong Q.S., Zheng L.D., Wang L., Zeng F.Q., Chen F.M., Dong J.H., et al. Down-regulation of XIAP expression induces apoptosis and enhances chemotherapeutic sensitivity in human gastric cancer cells. Cancer Gene Ther. 12 (2005) 509-514
150. Tortora G., Bianco R., Daniele G., et al. Overcoming resistance to molecularly targeted anticancer therapies: rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. Drug Resist. Updates 10 (2007) 81-100
151. Tsunemitsu Y., Kagawa S., Tokunaga N., Otani S., Umeoka T., Roth J.A., et al. Molecular therapy for peritoneal dissemination of xenotransplanted human MKN-45 gastric cancer cells with adenovirus mediated Bax gene transfer. Gut 53 (2004) 554-560
152. Tu S.P., Cui J.T., Liston P., Huajiang X., Xu R., Lin M.C., et al. Gene therapy for colon cancer by adeno-associated viral vector-mediated transfer of survivin Cys84Ala mutant. Gastroenterology 128 (2005) 361-375
153. Tu S.P., Jiang X.H., Lin M.C., Cui J.T., Yang Y., Lum C.T., et al. Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer. Cancer Res. 63 (2003) 7724-7732
154. Van Geelen C.M.M., de Vries E.G.E., and de Jong S. Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy. Drug Resist. Updates 7 (2004) 345-358
155. Verhagen A.M., Ekert P.G., Pakusch M., Silke J., Connolly L.M., Reid G.E., et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 102 (2000) 43-53
156. Verhagen A.M., Silke J., Ekert P.G., Pakusch M., Kaufmann H., Connolly L.M., et al. HtrA2 promotes cell death through its serine protease activity and its ability to antagonize inhibitor of apoptosis proteins. J. Biol. Chem. 277 (2002) 445-454
157. Vucic D. Targeting IAP (inhibitor of apoptosis) proteins for therapeutic intervention in tumors. Curr. Cancer Drug Targets 8 (2008) 110-117
158. Wang P., Ni K.Y., and Zhou G.H. Association of IL1B polymorphisms with gastric cancer in a Chinese population. Clin. Biochem. 40 (2007) 218-225
159. Wang Z., Li Y., Liu E.T., and Yu Q. Susceptibility to cell death induced by blockade of MAPK pathway in human colorectal cancer cells carrying Ras mutations is dependent on p53 status. Biochem. Biophys. Res. Commun. 322 (2004) 609-613
160. Wiedenmann N., Koto M., Raju U., Milas L., and Mason K.A. Modulation of tumor radiation response with G3139, a Bcl-2 antisense oligonucleotide. Invest. New Drugs 25 (2007) 411-416
161. Wiedmann M.W., and Caca K. Molecularly targeted therapy for gastrointestinal cancer. Curr. Cancer Drug Targets 5 (2005) 171-193
162. Wong B.C., Jiang X., Fan X.M., Lin M.C., Jiang S.H., Lam S.K., et al. Suppression of RelA/p65 nuclear translocation independent of IκBα degradation by cyclooxygenase-2 inhibitor in gastric cancer. Oncogene 22 (2003) 1189-1197
163. Wong B.C.Y., Michell N.M., and Langman M.J.S. Gastroenterology 110 (1996) A615
164. Wong S.F. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer. Clin. Ther. 27 (2005) 684-694
165. Wright C.W., and Duckett C.S. Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function. J. Clin. Invest. 115 (2005) 2673-2678
166. Wu J., Xia H.H., Tu S.P., Fan D.M., Lin M.C., Kung H.F., et al. 5-Lipoxygenase-1 mediates cyclooxygenase-2 inhibitor-induced apoptosis in gastric cancer. Carcinogenesis 24 (2003) 243-247
167. Xia L., Zhang D., Du R., Pan Y., Zhao L., Sun S., et al. miR-15b and miR-16 modulate multidrug resistance by targeting Bcl2 in human gastric cancer cells. Int. J. Cancer 123 (2008) 372-379
168. Yang J.H., Zhang Y.C., and Qian H.Q. Survivin antisense oligodeoxynucleotide inhibits growth of gastric cancer cells. World J. Gastroenterol. 10 (2004) 1121-1124
169. Yano S., Kondo K., Yamaguchi M., Richmond G., Hutchison M., Wakeling A., et al. Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition. Anticancer Res. 23 (2003) 3639-3650
170. Yoshida T., Okamoto I., Okabe T., Iwasa T., Satoh T., Nishio K., et al. Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk. Int. J. Cancer 122 (2008) 1530-1538
171. Yotsumoto F., Yagi H., Suzuki S.O., Oki E., Tsujioka H., Hachisuga T., et al. Validation of HB-EGF and amphiregulin as targets for human cancer therapy. Biochem. Biophys. Res. Commun. 365 (2008) 555-561
172. Yu H.G., Ai Y.W., Yu L.L., Zhou X.D., Liu J., Li J.H., et al. Phosphoinositide 3-kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death. Int. J. Cancer 122 (2008) 433-443
173. Yu L.F., Wang J., Zou B., Lin M.C., Wu Y.L., Xia H.H., et al. XAF1 mediates apoptosis through an extracellular signal-regulated kinase pathway in colon cancer. Cancer 109 (2007) 1996-2003
174. Zhang W., Tong Q., Li S., Wang X., and Wang Q. MG-132 inhibits telomerase activity, induces apoptosis and G(1) arrest associated with upregulated p27kip1 expression and downregulated survivin expression in gastric carcinoma cells. Cancer Invest. 26 (2008) 1032-1036
175. Zhang L., Ming L., and Yu J. BH3 mimetics to improve cancer therapy; mechanisms and examples. Drug Resist. Updates 10 (2007) 207-217
176. Zhou X.M., Wong B.C., Fan X.M., Zhang H.B., Lin M.C., Kung H.F., et al. Non-steroidal anti-inflammatory drugs induce apoptosis in gastric cancer cells through up-regulation of Bax and Bak. Carcinogenesis 22 (2001) 1393-1397
177. Zhou Y., Li S., Hu Y.P., Wang J., Hauser J., Conway A.N., et al. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis. Cancer Res. 66 (2006) 404-411
178. Zhou Y., Ran J., Tang C., Wu J., Honghua L., Xingwen L., et al. Effect of celecoxib on E-cadherin, VEGF, microvessel density and apoptosis in gastric cancer. Cancer Biol. Ther. 6 (2007) 269-275
179. Zhu Q., Liu J.Y., Xu H.W., Yang C.M., Zhang A.Z., Cui Y., et al. Mechanism of counterattack of colorectal cancer cell by Fas/Fas ligand system. World J. Gastroenterol. 11 (2005) 6125-6129
180. Zhu G.H., Wong B.C., Eggo M.C., Ching C.K., Yuen S.T., Chan E.Y., et al. Non-steroidal anti-inflammatory drug-induced apoptosis in gastric cancer cells is blocked by protein kinase C activation through inhibition of c-myc. Br. J. Cancer 79 (1999) 393-400
181. Zhu G.H., Wong B.C., Slosberg E.D., Eggo M.C., Ching C.K., Yuen S.T., et al. Overexpression of protein kinase C-β1 isoenzyme suppresses indomethacin-induced apoptosis in gastric epithelial cells. Gastroenterology 118 (2000) 507-514